PhenoModifier-Variant Detail

Variant "TCF7L2:c.382-41435C>T"

Search result: 1 record

Variant information

Gene:

TCF7L2

Variant:

TCF7L2:c.382-41435C>T

Genomic location:

chr10:114758349(hg19)

HGVS:

SO Term	RefSeq
protein_coding	NM_001146274.1:c.450+33966C>T
protein_coding	NM_001146283.1:c.382-41435C>T
protein_coding	NM_001146284.1:c.382-41435C>T
protein_coding	NM_001146285.1:c.382-41435C>T
protein_coding	NM_001146286.1:c.382-41435C>T
protein_coding	NM_001198525.1:c.382-41435C>T
protein_coding	NM_001198526.1:c.382-41435C>T
protein_coding	NM_001198527.1:c.382-41435C>T
protein_coding	NM_001198528.1:c.382-41435C>T
protein_coding	NM_001198529.1:c.382-41435C>T
protein_coding	NM_001198530.1:c.381+46983C>T
protein_coding	NM_001198531.1:c.450+33966C>T
protein_coding	NM_030756.4:c.382-41435C>T
show all

dbSNP ID:

rs7903146

GWAS trait:

physical activity measurement,body mass index,smoking behavior,type II diabetes mellitus,waist circumference,hip circumference,peak insulin response measurement,clinical laboratory measurement,glucose measurement,fasting blood insulin measurement,fasting blood glucose measurement,insulin measurement,metabolic syndrome,A1C measurement,autoantibody measurement,schizophrenia

Modifier statisitcs

Record:

1

Disorder:

1

Reference:

1

Effect type:

Expressivity(1)

Modifier effect:

Altered severity(1)

Detail：

Target disease:

Nonalcoholic Fatty Liver Disease (DOID_0080208)

Effect type:

Expressivity

Modifier effect:

Altered severity

Evidence:

P=0.0001

Effect:

Associated with the development NAFLD or disease severity.

Reference:

PMID26740948

Title:

Genetic analysis of nonalcoholic fatty liver disease within a Caribbean-Hispanic population.

Species studied:

Human

Abstract:

We explored potential genetic risk factors implicated in nonalcoholic fatty liver disease (NAFLD) within a Caribbean-Hispanic population in New York City. A total of 316 individuals including 40 subjects with biopsy-proven NAFLD, 24 ethnically matched non-NAFLD controls, and a 252 ethnically mixed random sampling of Bronx County, New York were analyzed. Genotype analysis was performed to determine allelic frequencies of 74 known single-nucleotide polymorphisms (SNPs) associated with NAFLD risk based on previous genome-wide association study (GWAS) and candidate gene studies. Additionally, the entire coding region of PNPLA3, a gene showing the strongest association to NAFLD was subjected to Sanger sequencing. Results suggest that both rare and common DNA variations in PNPLA3 and SAMM50 may be correlated with NAFLD in this small population study, while common DNA variations in CHUK and ERLIN1, may have a protective interaction. Common SNPs in ENPP1 and ABCC2 have suggestive association with fatty liver, but with less compelling significance. In conclusion, Hispanic patients of Caribbean ancestry may have different interactions with NAFLD genetic modifiers; therefore, further investigation with a larger sample size, into this Caribbean-Hispanic population is warranted.